Ten-year antibody persistence induced by hepatitis A and B vaccine (Twinrix™) in adults

SummaryBackgroundHepatitis A and B infections are prevalent worldwide and cause significant morbidity and mortality. A combined vaccine providing dual protection against hepatitis A and B is available (Twinrix®, GlaxoSmithKline Biologicals).MethodTwo cohorts of adults aged 17–43 years were vaccinated with Twinrix® according to a 0, 1, 6 months schedule and followed up for 10 years.ResultsOne month after the primary vaccination course (Month 7), all subjects were seropositive for anti-HAV and all had anti-HBs⩾10 mIU/ml. At month 120, 100% of subjects (N=34; N=29) in both cohorts were seropositive for anti-HAV; 94.1% and 86.2% of subjects had anti-HBs⩾10 mIU/ml. The geometric mean concentrations (GMC; mIU/ml) were 373.9 and 674.6 in the two cohorts for anti-HAV, and 103.8 and 320.0, respectively, for anti-HBs. None of the serious adverse events reported throughout the follow-up period were considered by the investigator to be causally related to vaccination.ConclusionsCombined hepatitis A and B vaccine, Twinrix®, is safe, well-tolerated and has demonstrated a highly immunogenic profile. Persistence of anti-HAV and anti-HBs antibodies in adults remains high for at least 10 years after primary vaccination.